|

[68]Ga-HA-DOTATATE Clinical Trials

1 actively recruiting trial

Also known as: Gallium-68 DOTA-3-iodo-Tyr(3)-octreotate, Gallium-68 high affinity-DOTATATE

Pipeline

Phase 1/2: 1

Top Sponsors

  • AHS Cancer Control Alberta1

Indications

  • Neuroendocrine Tumors1
  • Cancer1

Other1 trial

A Study to Evaluate a New Way to Identify/Diagnose Tumours With Somatostatin Receptors Using [68]Ga-HA-DOTATATE and to Ensure it is Safe to Use
Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.